Literature DB >> 23240985

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

N Lynn Ferguson1, John Bell, Robert Heidel, Solomon Lee, Stuart Vanmeter, Lisa Duncan, Barbara Munsey, Timothy Panella, Amila Orucevic.   

Abstract

Estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2) status are well-established prognostic markers in breast cancer management. The triple negative breast carcinoma subtype (ER-/PR-/HER2-) has been associated with worse overall prognosis in comparison with other subtypes in study populations consisting of ethnic minorities and young women. We evaluated the prognostic value of breast cancer subtypes, Ki-67 proliferation index (Ki-67PI), and pathologic tumor characteristics on breast cancer survival in Caucasian women in our institution, where greater than 90% of the total patient population is white. From 628 new invasive breast cancer cases in our data base (2000-late 2004), 593 (94%) were identified in Caucasian women. ER/PR/HER2 breast cancer subtypes were classified based on St. Gallen International Expert Consensus recommendations from 2011. ER/PR/HER2 status and its effect on survival were analyzed using a Kaplan-Meier curve. ER/PR/HER2 status, grade, tumor-node-metastasis status (TNM)/anatomic stage, and age were analyzed in terms of survival in a multivariate fashion using a Cox regression. Ki-67PI was analyzed between ER/PR/HER2 groups using the Kruskal-Wallis, Mann-Whitney U-tests, and 2 × 5 ANOVA. Our results showed that patients with stage IIB through stage IV breast carcinomas were 2.1-16 times more likely to die than patients with stages IA-B and IIA disease, respectively (95% CI 1.17-3.81 through 9.68-28.03, respectively), irrespective of ER/PR/HER2 subtype. Similar effect was seen with T2, N2/N3, or M1 tumors in comparison with T1, N0/N1, and M0 tumors. Chances of dying increase approximately 5% for every year increase in age. There was a significant main effect of Ki-67PI between ER/PR/HER2 subtypes, p < .001, but Ki-67PI could not predict survival. In summary, TNM status/anatomic stage of breast carcinomas and age are predictive of survival in our patient population of Caucasian women, but breast carcinoma subtypes and Ki-67 proliferation index are not.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23240985     DOI: 10.1111/tbj.12059

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  33 in total

1.  MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.

Authors:  Einas M Yousef; Daniela Furrer; David L Laperriere; Muhammad R Tahir; Sylvie Mader; Caroline Diorio; Louis A Gaboury
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

Review 2.  Prognostic value of survivin expression in breast cancer patients: a meta-analysis.

Authors:  Jian Song; Hong Su; Yang-Yang Zhou; Liang-Liang Guo
Journal:  Tumour Biol       Date:  2013-05-21

3.  Basal ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer.

Authors:  Ana María García Vicente; Ángel Soriano Castrejón; Jesús Fernando López-Fidalgo; Mariano Amo-Salas; María Del Mar Muñoz Sanchez; Ruth Álvarez Cabellos; Ruth Espinosa Aunión
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-09       Impact factor: 9.236

4.  Outcomes in Patients with pT1-T2, pN0-N1 Breast Cancer After Conservative Surgery and Whole-breast Radiotherapy.

Authors:  Marianna Trignani; Clelia DI Carlo; Carmen Cefalogli; Marianna Nuzzo; Lucia Anna Ursini; Luciana Caravatta; Francesca Perrotti; Marta DI Nicola; Ambra Pamio; Domenico Genovesi
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

5.  Prognostic Factors in Operated Stage IIIC, Pathological N3a Breast Cancer Patients.

Authors:  Ibrahim Turker; Ulku Y Arslan; Ozan Yazici; Ummugul Uyeturk; Berna Oksuzoglu; Burcin Budakoglu; Nuriye Özdemir; Ozlem U Sonmez; Kaan Helvaci; Onur Esbah; Oznur Bal; Ahmet S Ekinci; Nurullah Zengin
Journal:  Breast Care (Basel)       Date:  2014-12       Impact factor: 2.860

6.  Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation.

Authors:  Zhongliang Ma; Jinlian Song; Simin Liu; Linlin Han; Yangping Chen; Yaqiu Wang; Chundong Yu; Lin Hou
Journal:  Oncol Lett       Date:  2016-09-16       Impact factor: 2.967

Review 7.  Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis.

Authors:  Fei Pan; Hui Mao; Ling Deng; Guangchao Li; Peiliang Geng
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

8.  Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study.

Authors:  Jinzhong Sun; Chuang Chen; Wen Wei; Hongmei Zheng; Jingping Yuan; Y I Tu; Feng Yao; Lijun Wang; Xiaoli Yao; Juanjuan Li; Yan Li; Shengrong Sun
Journal:  Oncol Lett       Date:  2015-07-06       Impact factor: 2.967

9.  Relative and disease-free survival for breast cancer in relation to subtype: a population-based study.

Authors:  Pamela Minicozzi; Francesca Bella; Angela Toss; Adriano Giacomin; Mario Fusco; Maurizio Zarcone; Rosario Tumino; Fabio Falcini; Rosaria Cesaraccio; Giuseppa Candela; Francesco La Rosa; Massimo Federico; Milena Sant
Journal:  J Cancer Res Clin Oncol       Date:  2013-07-28       Impact factor: 4.553

10.  Epidemiology and prognosis of breast cancer in young women.

Authors:  Hussein A Assi; Katia E Khoury; Haifa Dbouk; Lana E Khalil; Tarek H Mouhieddine; Nagi S El Saghir
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.